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It is unclear whether serum adiponectin concentrations diminish linearly with increasing adiposity and, if not, 
which factors codetermine this association. These issues were investigated cross-sectionally in 1188 men and 
women, representative of middle-aged and elderly Turkish adults. Serum total adiponectin was assayed by 
ELISA. Serum adiponectin values in men, though declining significantly in transition from the bottom to the mid 
tertile of body mass index (BMI) and waist circumference (WC), were similar in the two respective upper tertiles. 
In women, serum adiponectin concentrations were not significantly different in any tertile of these indices, were 
significantly correlated with BMI or WC within the low tertiles and not within the two higher tertiles. In a linear 
regression analysis for WC (or BMI) in a subset of the sample in which serum sex hormone-binding globulin 
(SHBG) was available and which additionally comprised adiponectin, fasting insulin and other confounders, 
only insulin and, in women SHBG, were significantly associated, but not adiponectin. In linear regression 
analyses for covariates of adiponectin in two models comprising 12 variables, insulin and SHBG concentrations 
were significantly associated in both genders though not BMI. Whereas in men HDL-cholesterol and CRP were 
covariates of adiponectin (both p<0.01), SHBG and apolipoprotein B positively associated in women (p<0.001), 
independent of BMI and fasting insulin levels.  
Conclusions: Relationship between excess adiposity and adiponectin levels is inconsistent in Turkish adults. In-
dependently from obesity and hyperinsulinemia, serum adiponectin discloses significant relationship with in-
flammatory markers and HDL only in men, not in women in whom it is influenced by SHBG, with consequent 
attenuation of its anti-inflammatory activities. 
Key words: Adiponectin, anti-inflammatory function, gender difference, waist circumference, obesity, sex hormone-binding 
globulin 
Introduction 
In vitro studies and animal experiments have 
demonstrated that adiponectin, the cytokine synthe-
sized by adipocytes, possesses antiatherogenic, insu-
lin-sensitizing and antiinflammatory properties. In 
humans, however, conflicting results have been re-
ported between serum adiponectin and coronary heart 
disease (CHD) [1-3] in one of which [3] was suggested 
that there may be a true sex difference in the associa-
tion of adiponectin with coronary heart disease. 
Moreover, the theoretical hypothesis of ‘adiponectin 
resistance’ was put forward due to the observation of a 
positive association of plasma adiponectin concentra-
tion and age in men, and it was conjectured whether 
the implication of hypoadiponectinemia in youth 
might be different from old age [4]. ‘Adiponectin 
paradox’ [5], namely a high adiponectin level being a 
predictor of mortality has been repeatedly observed in 
patients with chronic heart failure [6], particularly in 
subjects with normal body mass index (BMI) [6], sug-
gesting that the prognostic significance of adiponectin Int. J. Biol. Sci. 2008, 4 
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in this condition is affected by BMI. Furthermore, ele-
vated adiponectin levels independently predicted ad-
verse outcomes in 325 male patients presenting with 
chest pain which was attributed to either the underly-
ing inflammatory state or to adiponectin resistance [7]. 
Whether the relation of adiponectin concentra-
tions with indices of obesity is of linear shape at in-
creasing degrees of obesity in diverse ethnic groups 
needs further exploring, particularly as the relation of 
dyslipidemia with increasing abdominal obesity is of 
asymptotic shape among Turkish adults, particularly 
in women [8,9]. We recently reported also that sex 
hormone-binding globulin (SHBG) is an important 
determinant of dyslipidemia and cardiometabolic dis-
orders, especially in women, independent of abdomi-
nal obesity and insulin resistance [10] which warrants 
the investigation also of the association between SHBG 
and adiponectin levels. 
Thus, the aim of this study was to evaluate: 1) the 
nature and linearity of the association between differ-
ent indicators of obesity and serum adiponectin levels, 
2) whether or not anticipated inverse associations be-
tween adiponectin and HDL-cholesterol, triglyc-
erides/apo B and CRP exist independent of BMI or 
waist circumference, 3) whether SHBG plays an inde-
pendent role on concentrations of adiponectin in 
Turkish men and women in whom both atherogenic 
dyslipidemia and MetS prevail [11]. 
 
Population and Methods 
Sample population 
This study sample was recruited randomly in an 
approximately three-fifth proportion of participants of 
the 2005/06 follow-up survey of the Turkish Adult Risk 
Factor Study, an ongoing study on the prevalence of 
cardiac disease and risk factors in a representative 
sample of adults in Turkey carried out periodically 
almost biennially since 1990 in 59 communities 
throughout all geographical regions of the country 
[12]. Details of the overall sampling were described 
previously [13]. The study was approved by the Ethics 
Committee of the Istanbul University Medical Faculty. 
Written informed consent was obtained from all par-
ticipants. Partial logistic support was provided by the 
Turkish Ministry of Health. Data were obtained by 
history of the past years via a questionnaire, physical 
examination of the cardiovascular system, sampling of 
blood and recording of a resting 12-lead electrocar-
diogram. Serum concentrations of adiponectin were 
assayed among participants aged 37 to 79 years, re-
sulting in determinations in 561 men and 663 women, 
median age 54 years in each sex, 70% of whom was 
fasting. Twenty-two subjects who had serum 
creatinine concentrations ≥133/115 µmol/L in 
men/women, 3 subjects with adiponectin concentra-
tions >60 µg/ml and 11 persons with missing obesity 
measures were excluded, leaving 1188 (of whom 644 
female) individuals for analysis. This sample did not 
include any participants who reported suffering from 
acute inflammatory dlsease in the preceding month. 
The percentage of postmenopausal women was 65.6. 
The study group and the whole cohort were similar 
with respect to age, sex distribution, proportions of 
metabolic disorders. 
Measurement of risk factors  
Blood pressure was measured with an aneroid 
sphygmomanometer (Erka, Germany) in the sitting 
position on the right arm, and the mean of two re-
cordings 3 min apart was recorded. Height was meas-
ured without shoes using a measuring stick and 
weight in light indoor clothes using scales. Waist cir-
cumference was measured - with the subject standing 
and wearing only underwear, at the level midway 
between the lower rib margin and the iliac crest. BMI 
was computed as weight divided by height squared 
(kg/m2). In regard to cigarette smoking, nonsmokers, 
former smokers and current smokers formed the 
categories.  
Blood samples were collected, spun at 1000g for 10 
minutes and shipped on cooled gel packs at 2-5oC to 
Istanbul to be stored in deep-freeze at -75oC, until 
analyzed at the Yıldız Technical University. Serum 
concentrations of hsC-reactive protein (CRP), apoli-
poprotein (apo) B and apo A-I were measured by 
nephelometry (BN Prospec, Behring Diagnostics, 
Westwood, MA). Serum concentration of adiponectin 
was assayed by a sandwich enzyme-linked immu-
nosorbent assay system (Adiponectin ELISA BioVen-
dor, BioVendor Lab. Medicine, Inc, Czech Rep.) at the 
Acibadem Labmed, Istanbul. Within-run and 
day-to-day coefficients of variation for adiponectin 
measurements were 4% and <10%, respectively. Serum 
concentrations of total cholesterol, fasting triglyc-
erides, glucose, HDL-cholesterol (HDL-C plus 2nd 
generation, directly without precipitation) and 
LDL-cholesterol (directly) were determined by using 
enzymatic kits from Roche Diagnostics (Mannheim, 
Germany) with a Hitachi 902 autoanalyzer. Serum 
concentrations of SHBG and insulin were carried out 
by the electrochemiluminescence immunoassay 
ECLIA on Roche Elecsys 2010 using Roche kits (Roche 
Diagnostics, Mannheim, Germany). Homeostatic 
model assessment (HOMA) was calculated with the 
following formula [14]: insulin (mIU/L)* glucose (in 
mmol/L)/ 22.5.   Int. J. Biol. Sci. 2008, 4 
 
210
Data analysis  
Descriptive parameters were shown as mean ± 
standard deviation and in percentages. Due to the 
skewed distribution, values derived from 
log-transformed (geometric) means and standard error 
(SE) were used for adiponectin, CRP, insulin, HOMA 
and SHBG. Pearson correlation tests were made for 
continuous and log-transformed variables. The popu-
lation sample was divided into tertiles of BMI (by cut-
off points of 25.88 and 29.3 kg/m² in men, 27.9 and 
32.47 kg/m² in women), of WC (by cutoff points of 91 
and 101 cm in men, 87 and 98 cm in women) and of hip 
circumference (by 98 and 104 cm in men, 102 and 112 
cm in women). Pairwise comparisons with Bonferroni 
adjustments were made to detect significance between 
groups of estimated means; two-sided t-tests and 
Pearson’s chi-square tests were used to analyze the 
differences between means and proportions of other 
groups. Multiple linear regression analyses were per-
formed with continuous parameters, adjusted also for 
usage of antihypertensive, antidiabetic and lipid low-
ering drugs, and the presence of CHD. A value of 
p<0.05 on the two-tail test was considered statistically 
significant. Statistical analyses were performed using 
SPSS-10 for Windows.   
Results 
This sample of a general population comprised 
individuals with type-2 diabetes in 13.2% and with 
CHD in 12.4%. Geometric mean value of serum adi-
ponectin concentrations in the entire sample was 
9.84±1.70 µg/ml; in the nonfasting state, only 1.6% 
lower (p=0.49) than the 9.89±1.70 µg/ml among fasting 
participants. Table 1 shows the distribution of main 
characteristics of the population sample across tertiles 
of BMI. Only HDL-cholesterol, triglycerides, apo B, 
fasting insulin, HOMA index, SHBG, CRP and adi-
ponectin concentrations were significantly different in 
the bottom tertile (lean individuals) from those in the 
other tertiles. In contrast, top tertile (obese individuals) 
differed significantly (p<0.01) from the mid tertile only 
in HOMA index and concentrations of insulin and 
CRP. Significant variables were similarly distributed 
across tertiles of WC. In this sample with no elevated 
serum creatinine values, partial correlation coefficients 
for adiponectin with creatinine, controlled for age, 
were -0.13, p=0.003 in men and -0.04, p=0.35 in 
women. In Table 1, certain variables are presented 
separately for women as well. These show a similar 
distribution in the BMI tertiles except for 
HDL-cholesterol which does not significantly decline 
in the mid-tertile. 
Table 1. Distribution of adiponectin, markers of dyslipidemia and insulin resistance across sex-specific BMI tertiles (n= 1188), and 
separately in women 
  Low tertile  Mid- tertile  High tertile     
   n  mean  SD/ 
SE 
mean SD  mean SD  ANOVA 
p-value 
p-value* 
Age, y       Men  544  53.4  11.8  54.1  11.2  54.0  10.4  0.82  0.82 
      Women 644  52.2  12.3  53.7  11.1  55.0  10.5  0.043  0.35 
Adiponectin ¶, µg/ml   Men  544  9.64  1.75  8.07 1.61  8.09 1.64  0.001  0.003 
      Women 644  11.66  1.77 10.36 1.66 10.4  1.69  0.035  0.057 
Creatinine,  mg/dl    1115 0.865  0.19 0.873 0.19 0.886 0.19  NS  0.30 
Total cholesterol, mmol/l    1184  5.11  1.18  5.17  1.16  5.11  1.03  NS  0.72 
LDL-cholesterol,  mmol/l    1139 3.04  0.91 3.1  0.92 2.99  0.85  NS  0.63 
HDL-cholest.,mmol/l   Men  538  1.17  0.31 1.11  0.29 1.07  028 <0.001  <0.001 
      Women 640  1.23  0.31 1.21  0.29 1.14  0.28 0.006 0.74 
F.triglyceride, mmol/l   Men  489  1.67  1.09  1.98 1.23  2.01 1.29  0.017  0.049 
 Women  607  1.63  1.21  1.81 1.32  1.84 1.0  0.15  0.17 
ApolipoproteinA-I,g/l   Men  494 1.366  .29 1.321  .23 1.35 .24  0.26  0.24 
  Women  583 1.496  .27 1.474  .31 1.458  .26  0.44  0.40 
Apolipoprotein B, g/l   Men  494  0.993  .25  1.086 .48  1.055 .27  0.049  0.041 
  Women  589 1.02  .31 1.084  .32 1.06 .33  0.13  0.11 
Fast. insulin,¶ mIU/L   Men  438 5.35  2.49 8.53  1.86 12.7  2.06 <0.001  <0.001 
      Women 540  6.84  2.00 8.61  1.88 11.1  1.80 <0.001  0.001 
HOMA index¶     Men  422  1.17  2.68 1.87  1.85 2.94  2.27 <0.001  <0.001 
      Women 537  1.51  2.14 2.05  2.05 2.69  2.00 <0.001  0.001 
C-reactive protein, mg/L  Men  505  1.56  2.98  1.97 2.87  2.60 2.66  <0.001  0.11 
      Women 610  1.64  3.19  2.69 1.68  3.24 2.60  <0.001  0.001 
SHBG, nmol/L¶    Men  267  52.6  1.61  42.1 1.54  39.7 1.55  <0.001  0.001 
      Women 274  64.7  1.79  49.9 1.68  43.9 1.56  <0.001  0.003 
¶log-transformed 
*between bottom and mid tertiles, significant values indicated in bold 
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The distribution of mean adiponectin values as 
well as their correlation with markers of obesity across 
tertiles of BMI and WC is provided in Fig. 1, separately 
in the sexes. Adiponectin concentrations in men were 
reduced significantly in the mid and top tertiles rela-
tive to the bottom tertile, but were similar in the mid 
and top tertiles of both obesity measures. Adiponectin 
concentrations among women were similar across ter-
tiles of both obesity indices. Significant inverse corre-
lation between adiponectin and obesity measures was 
observed only within the low tertiles of BMI but, oth-
erwise, not within the two higher tertiles. Postmeno-
pausal women exhibited essentially the same features 
as the whole female group. 
 
 
Fig. 1. Mean values of log-transformed adiponectin concentra-
tions stratified by tertiles of waist circumference (WC) and body 
mass index (BMI) in 544 men and 644 women. Asterisks denote 
significant (p<0.013) differences. Shaded bars indicate signifi-
cant inverse correlation of adiponectin within the related tertile. 
Mean values of obesity indices in each mid tertile among men 
and women were as follows: 96 – 92.5 cm; 27.7 – 30.2 kg/m². 
 
Two regression models were formed seeking 
linear relationship of serum adiponectin (p<0.001) 
which explained 13-20% of the variance of adiponectin 
both involving sex, age, insulin, HDL-cholesterol, apo 
B and SHBG (Table 2). In the first model waist girth 
and triglycerides were comprised, in the second model 
BMI tertiles, CRP, prevalent coronary disease and us-
age of antihypertensive, antidiabetic and lipid lower-
ing drugs. While waist girth or BMI tertiles were not 
associated, fasting insulin and SHBG were the only 
significant covariates of adiponectin in both sexes. 
HDL-cholesterol, apo B and CRP, parameters related 
to pro- and anti-inflammatory processes, showed dif-
ferent associations in the sexes. Whereas adiponectin 
revealed anticipated reciprocal associations in males, 
no association was noted in females in whom adi-
ponectin was positively associated (p=0.034).   
Table 3 shows results of a further linear regres-
sion analyses for covariates of serum adiponectin as 
the dependent variable and including also testoster-
one, smoking status (not significant), BMI and waist 
circumference, triglycerides and CRP; as in previous 
models, availability of SHBG measurement limited the 
sample to less than half the size. Apart from being de-
termined by female sex (1.34-fold, p<0.001), serum 
adiponectin was significantly associated not with obe-
sity measures. Inverse association with triglycerides 
and CRP existed in men, in addition to a positive one 
with testosterone level (1.23-fold), but in women, only 
SHBG was associated [ß-coefficient 2.07, p<0.001].  
Table 2. Linear regression for serum adiponectin,¶ (µg/ml) as 
dependent variable 
Men n= 229  Women n= 246   
ß coeff.  p-value  ß coeff.  p-value 
Fasting insulin,¶ mIU/l  0.81  0.029  0.79  0.041 
SHBG,¶ nmol/l  1.40  0.073  2.05  <0.001 
HDL-cholesterol, mg/dl 1.015  <0.001 1.001  0.62 
Apolipoprotein B, mg/l  1.000  0.58  1.002  0.034 
Waist circumference, cm 1.00  0.95  1.001  0.65 
 
Models were significant (p<0.001) explaining 19% of variance of 
adiponectin in men and 15% in women. Models included also sex 
(1.172, p=0.001), age and triglycerides, both not significant. 
 
Fasting insulin,¶ mIU/l  0.782  0.012  0.809  0.071 
SHBG,¶ nmol/l  1.49  0.031  2.03  <0.001 
HDL-cholesterol, mg/dl 1.014  <0.001 1.002  0.53 
C-reactive protein,¶ 
mg/l 
0.848  0.18 0.991  0.91 
BMI tertiles  1.069  0.13  1.013  0.78 
 
Models were significant (p<0.001) explaining 20% of variance of 
adiponectin in men and 13% in women. Models included also sex 
(1.20, p<0.001), age, apolipoprotein B, usage of antihypertensive, 
antidiabetic and lipid lowering drugs and prevalent coronary dis-
ease, none significant. 
¶ log-transformed values   
The 205 postmenopausal women were not significntly different from 
the entire female group. 
Table 3. Linear regression for serum adiponectin,¶ (µg/ml) as 
dependent variable 
Men n= 244  Women n= 264   
ß coeff.  p-value  ß coeff.  p-value 
Testosterone,¶ nmol/l  1.23  0.041 1.008  0.92 
SHBG,¶ nmol/l  1.46  0.051  2.07  <0.001 
F. triglycerides, mg/dl  0.9994  0.042 1.000  0.28 
C-reactive protein,¶ 
mg/l 
0.824  0.051 0.994  0.92 
Models were significant (p<0.001) explaining 18% of variance of 
adiponectin in men and 10% in women. Models included also sex 
(1.34, p=0.001), age (p=0.012 in men), smoking status, BMI and waist 
circumference, none significant. 
¶ log-transformed values   
Discussion 
In this cross-sectional study on middle-aged and 
elderly Turkish adults, we have shown that serum 
adiponectin was not linearly associated with measures Int. J. Biol. Sci. 2008, 4 
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of overall or abdominal obesity when controlled for 
insulin and SHBG. In fact, except for lean subjects, 
there was a total lack of association of obesity meas-
ures with adiponectin. Serum adiponectin values dis-
played a threshold effect with increasing obesity, be-
yond which concentrations did not significantly de-
cline. In multivariable linear analyses, adiponectin 
levels were significantly associated with 
HDL-cholesterol and CRP, independent of BMI and 
fasting insulin levels only in men while being in 
women positively associated with apo B, an inflam-
matory marker [15], and with SHBG. These three novel 
findings, namely, a threshold effect, evidence of a 
gender difference in anti-inflammatory properties of 
adiponectin and an independent association of low 
SHBG with moderately low adiponectin levels in 
women may lead to the generation of a hypothesis for 
women that adiponectin possesses impaired 
anti-inflammatory properties, likely influenced by 
SHBG levels, while the emergence of an inverse rela-
tionship between obesity and adiponectin levels is 
precluded. 
Lack of inverse association between obesity indices and 
serum adiponectin among obese persons 
It is generally considered that plasma adiponectin 
levels decrease with increasing obesity. A salient 
finding of the present analysis is the lack of further 
change of adiponectin values in the transition to high 
tertiles of obesity measures beyond the mid tertile, 
regardless of genders. This suggests an impaired rela-
tionship of adiponectin with adiposity in this popula-
tion. An inverse association could not be demonstrated 
in multiple linear regression analyses between adi-
ponectin and measure(s) of (abdominal) obesity in 
either gender. This is in partial agreement with the 
recent work of Yasui et al. [16] in which serum adi-
ponectin concentrations in postmenopausal women 
alone were neither correlated, nor associated with BMI 
independently of SHBG but were so among men. 
Reports on the role of lower body fat mass on 
adiponectin have yielded conflicting results. An inde-
pendent positive role, partly explained by variations of 
adiponectin level, was observed in 401 men by Bue-
mann et al [17], and subcutaneous adipose tissue was a 
positive independent correlate of adiponectin in 
nondiabetic Americans [18]. A significant correlation 
between HC and adiponectin was, however, lacking in 
165 Asian Indian and Caucasian adults living in Can-
ada [19], and adiponectin was significantly inversely 
correlated with subcutaneous abdominal adipose tis-
sue in 148 women [20] or in 41 Caucasian men by 
computed tomography [21]. Taken together, these 
findings show a lack of a linear association of adi-
ponectin with (abdominal) obesity measures, and lev-
els fail to be reduced in response to increasing adipos-
ity.  
Synthesis and secretion of adiponectin by adipo-
cytes, or interaction with specific adiponectin receptors 
might be impaired in obese individuals. A state of 
adiponectin resistance was recently described in insu-
lin resistant mice with hyperadiponectinemia with 
normal levels of adiponectin receptor-1 and -2 and 
inability to lower glucose levels by adiponectin ad-
ministration [22]. In nonobese patients with chronic 
heart failure, high serum adiponectin paradoxically 
predicts mortality [5,6]; it is unclear whether the 
anti-inflammatory property of this protein is impaired 
under these conditions. 
Independent association of SHBG with adiponectin 
concentrations 
Our finding of testosterone being significantly 
associated with serum adiponectin is in line with the 
report of Nishizawa and coworkers [23] that andro-
gens, being suppresed with aging, decrease plasma 
adiponectin. The independent association of adi-
ponectin with SHBG has been sparsely investigated. In 
334 elderly Japanese men and women, SHBG was 
found to be a determinant of adiponectin in multi-
variate analysis in both genders, regardles of HOMA 
index, and in men alone, also independent of BMI [17]. 
Our multivariable analyses in women, by demon-
strating that SHBG is independently and inversely 
related to WC as well as to adiponectin levels, irre-
spective of obesity measures, insulin or CRP levels or 
of menopausal status, suggest that relatively low levels 
may be heterogenous and, indeed, be linked to adi-
ponectin functional defectiveness. This observation 
supports our recent report that low SHBG levels sig-
nificantly associate, particularly in women, with vari-
ous metabolic disorders, independent of abdominal 
obesity and insulin resistance [10] and suggests that 
this effect is mediated by adiponectin.  
Gender difference possibly affecting adiponectin’s 
anti-inflammatory function 
Present findings indicate that expected associa-
tions of adiponectin concentrations with 
HDL-cholesterol and CRP in men is independent of 
variations in SHBG and other relevant parameters 
such as obesity, insulin level and smoking status. This 
is in essential agreement with the recent report on the 
association of adiponectin in Japanese men with CRP 
independently of all MetS factors [24]. At distinct 
variance, in Turkish women, no independent positive 
relationship of adiponectin levels was observed with 
HDL-cholesterol, nor a reciprocal one with CRP, in 
fact, a positive association emerged with apo B, e.g. Int. J. Biol. Sci. 2008, 4 
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adiponectin depended on variations in SHBG and in-
sulin, regardless of inflammatory markers. This sug-
gests a concept that, the anti-inflammatory activities of 
adiponectin counteract two types of inflammatory 
processes, one related to obesity/insulin resistance, 
opposed by but not independently linked to adi-
ponectin, the other not related to obesity/insulin re-
sistance (rather perhaps to lipoproteins, hormones, 
chemokine attractant protein, adhesion molecules) and 
opposed by adiponectin. The latter type of 
anti-inflammatory properties manifested herein by 
significant independent associations between adi-
ponectin levels and CRP or HDL among men. In fe-
males of this sample, evidence of such dysfunction was 
observed. Impaired interaction with one of the known 
or unknown adiponectin receptors enhanced by low 
SHBG might be hypothesized as an underlying 
mechanism, perhaps with resulting interaction be-
tween adiponectin and apo B. It has been pointed out 
that SNPs for adiponectin receptor-1 gene were sig-
nificant in obese but not in combined lean and obese 
subjects, suggesting gene-environment interactions, 
such that polymorphisms may influence obe-
sity-associated comorbidities only when individual is 
obese [25]. 
This gender difference very likely explains the 
observation that low SHBG is an important determi-
nant of both diabetes and the dyslipidemia involving 
hypertriglyceridemia with elevated apo B in women 
(though not in men) independent of abdominal obesity 
and insulin resistance [10]. In studying a large sample 
of patients with coronary heart disease, van Eynatten 
et al. [26] found a lack of association of adiponectin 
with CRP which they attributed to a potential decrease 
of the role of systemic inflammation as part of the re-
lationship of adiponectin with atherosclerosis during 
the course of the disease. 
Further gender-related dysfunction of protective 
proteins have been newly observed in this sample of 
the adult Turkish population at large. As yet unpub-
lished observations provided evidence of 
anti-inflammatory and atheroprotective HDL dys-
function as well as indicated that high compared with 
low serum apo A-I levels independently increase the 
risk for incident diabetes. Collectively, these altera-
tions suggest that under circumstances of excess 
chronic low-grade inflammation associated with a 
high prevalence of obesity and cardiometabolic dis-
eases, several defense mechanisms such as activities of 
circulating protective proteins may be seriously at-
tenuated. 
The main limitation in this study is its 
cross-sectional nature with its attendant potential in-
ability to differentiate cause from effect. Though no 
significant difference was found between adiponectin 
concentrations of fasting and nonfasting subjects, a 
previously described slight diurnal variation in con-
centrations may not have been accounted in the cur-
rent analyses. Nonetheless, it is difficult to dispute that 
present findings provide convincing evidence of a lack 
of anti-inflammatory properties of adiponectin and a 
potential role of low SHBG in Turkish women therein. 
The study’s large sample size, being based on a repre-
sentative sample of a general population of both sexes, 
in which MetS prevailed highly, the range of obesity 
measures were wide, adjustments were made for such 
parameters as insulin, CRP, apo B and SHBG and va-
lidity shown also exclusively in menopausal women 
constitute strengths of the study. Results warrant ex-
ploration and confirmation in other ethnic popula-
tions. 
In conclusion, we found that circulating adi-
ponectin, not linearly associated with measures of 
overall or abdominal obesity, disclosed a lack of (in-
dependent) association with obesity measures and a 
threshold effect. Adiponectin failed to be linked with 
CRP and HDL and was positively associated with apo 
B in women, contrasted to men. Serum SHBG was 
significantly and independently associated with serum 
adiponectin levels among women. It may be hypothe-
sized that low SHBG in obese women is independently 
related to generation of functionally defective adi-
ponectin, which might not afford enough protection 
against inflammatory processes, obscuring the mani-
festation of an inverse relationship between obesity 
and adiponectin levels. Gender determines an inde-
pendence of such partial anti-inflammatory dysfunc-
tion of adiponectin from obesity. These observations 
implicate that moderately high adiponectin values in 
obese individuals should not be interpreted as neces-
sarily indicating low cardiometabolic risk; they may 
further provide insight into the strong inflammatory 
component underlying cardiometabolic risk in diverse 
ethnic populations. 
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